|
Variables
|
Overall survival
|
|---|
|
Univariable
|
Multivariable
|
|---|
|
HR (95% CI)
|
p value
|
HR (95% CI)
|
p value
|
|---|
|
Age (years)
|
0.988 (0.980, 0.996)
|
0.003
|
0.992 (0.984,1.000)
|
0.050
|
|
Male sex
|
1.442 (1.085, 1.917)
|
0.012
|
1.293 (0.967, 1.729)
|
0.083
|
|
Positive HBsAg
|
1.320 (0.995, 1.751)
|
0.054
| | |
|
Positive anti-HCV
|
0.634 (0.263, 1.531)
|
0.311
| | |
|
Child–Pugh grade B
|
1.340 (0.962, 1.886)
|
0.084
| | |
|
AFP ≥ 400 ng/mL
|
1.767 (1.482, 2.107)
|
< 0.001
|
1.346 (1.120, 1.618)
|
0.002
|
|
FAR
|
1.961 (1.632, 2.355)
|
< 0.001
|
1.230 (1.001, 1.510)
|
0.048
|
|
NLR
|
1.936 (1.611, 2.326)
|
< 0.001
|
1.045 (0.801, 1.362)
|
0.748
|
|
PLR
|
1.839 (1.466, 2.307)
|
< 0.001
|
0.739 (0.548, 0.998)
|
0.049
|
|
MLR
|
1.945 (1.632, 2.319)
|
< 0.001
|
1.166 (0.940, 1.446)
|
0.163
|
|
SII
|
2.210 (1.809, 2.700)
|
< 0.001
|
1.455 (1.053, 2.010)
|
0.023
|
|
CSPH
|
1.390 (1.050, 1.840)
|
0.021
|
1.369 (1.022, 1.833)
|
0.035
|
|
Ascites
|
1.471 (1.149, 1.883)
|
0.002
|
1.186(0.914, 1.539)
|
0.198
|
|
Cirrhosis
|
1.085 (0.910, 1.294)
|
0.364
| | |
|
Tumor size ≥ 5 cm
|
2.708 (2.200, 3.334)
|
< 0.001
|
1.500 (1.180, 1.907)
|
0.001
|
|
Multiple number
|
1.093 (0.871, 1.371)
|
0.441
| | |
|
MVI
|
3.484 (2.920, 4.156)
|
< 0.001
|
1.522 (0.711, 3.256)
|
0.279
|
|
BCLC stage C
|
8.773 (3.619, 21.267)
|
< 0.001
|
2.693 (0.835, 8.686)
|
0.097
|
|
Blood loss ≥ 400 ml
|
2.028(1.701, 2.417)
|
< 0.001
|
1.232 (1.011, 1.501)
|
0.039
|
|
Blood transfusion
|
1.554 (1.225, 1.971)
|
< 0.001
|
1.083 (0.843, 1.392)
|
0.534
|
|
Major hepatectomy
|
1.792 (1.498, 2.143)
|
< 0.001
|
1.075 (0.881, 1.311)
|
0.477
|
- HCC, hepatocellular carcinoma; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; AFP, alpha-fetoprotein; FAR, fibrinogen-albumin ratio; NLR, neutrophil–lymphocyte ratio; MLR, monocyte-lymphocyte ratio; PLR, platelet–lymphocyte ratio; SII, systemic immune–inflammation index; CSPH, clinically significant portal hypertension; MVI, macrovascular invasion; BCLC, Barcelona Clinical Liver Cancer
